ATE370941T1 - Modulatoren des vitamin-d-rezeptors - Google Patents

Modulatoren des vitamin-d-rezeptors

Info

Publication number
ATE370941T1
ATE370941T1 AT04819516T AT04819516T ATE370941T1 AT E370941 T1 ATE370941 T1 AT E370941T1 AT 04819516 T AT04819516 T AT 04819516T AT 04819516 T AT04819516 T AT 04819516T AT E370941 T1 ATE370941 T1 AT E370941T1
Authority
AT
Austria
Prior art keywords
vitamin
receptor
modulators
compounds
secosteroidal
Prior art date
Application number
AT04819516T
Other languages
English (en)
Inventor
Jianliang Lu
Tainwei Ma
Sunil Nagpal
Quanrong Shen
Alan Warshawsky
Ying Yee
Michael Rupp
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE370941T1 publication Critical patent/ATE370941T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04819516T 2003-11-20 2004-11-16 Modulatoren des vitamin-d-rezeptors ATE370941T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52360003P 2003-11-20 2003-11-20

Publications (1)

Publication Number Publication Date
ATE370941T1 true ATE370941T1 (de) 2007-09-15

Family

ID=34632799

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04819516T ATE370941T1 (de) 2003-11-20 2004-11-16 Modulatoren des vitamin-d-rezeptors

Country Status (8)

Country Link
US (2) US7582775B2 (de)
EP (1) EP1687292B1 (de)
JP (1) JP4717006B2 (de)
AT (1) ATE370941T1 (de)
CA (1) CA2544522A1 (de)
DE (1) DE602004008505T2 (de)
ES (1) ES2291981T3 (de)
WO (1) WO2005051940A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003101978A1 (en) * 2002-05-29 2003-12-11 Eli Lilly And Company Phenyl-thiophene type vitamin d receptor modulators
DE60326082D1 (de) 2002-11-22 2009-03-19 Lilly Co Eli Modulatoren von vitamin d rezeptoren
CA2544501A1 (en) 2003-11-20 2005-06-09 Eli Lilly And Company Vitamin d receptor modulators
EP1687289A1 (de) * 2003-11-20 2006-08-09 Eli Lilly And Company Modulatoren des vitamin-d-rezeptors
WO2005051940A2 (en) * 2003-11-20 2005-06-09 Eli Lilly And Company Vitamin d receptor modulators
EP1692123B1 (de) 2003-11-20 2008-05-28 Eli Lilly And Company Phenylfuranverbindungen als modulatoren des vitamin-d-rezeptors
US7750184B2 (en) 2003-11-20 2010-07-06 Eli Lilly And Company Vitamin D receptor modulators
ATE525354T1 (de) * 2004-05-03 2011-10-15 Janssen Pharmaceutica Nv Benzofuranderivate als selektive androgenrezeptormodulatoren (sarms)
KR100931777B1 (ko) * 2004-12-21 2009-12-14 일라이 릴리 앤드 캄파니 비타민 d 수용체 조절제
MX2007007439A (es) * 2004-12-21 2007-09-06 Lilly Co Eli Moduladores del receptor de la vitamina d.
EP1676834A1 (de) 2004-12-30 2006-07-05 Sanofi-Aventis Deutschland GmbH Kondensierte Bicyclische Carboxamid-Derivate zur Verwendung als CXCR2 Inhibitoren zur Behandlung von Entzündungen
JP5232144B2 (ja) 2006-06-28 2013-07-10 サノフイ Cxcr2阻害剤
JP5352454B2 (ja) 2006-06-28 2013-11-27 サノフイ Cxcr2アンンタゴニスト
MX2008015768A (es) 2006-06-28 2009-01-07 Sanofi Aventis Nuevos inhibidores de cxcr2.
JP5352455B2 (ja) 2006-06-30 2013-11-27 サノフイ Cxcr2阻害剤
CN108299425B (zh) * 2015-03-24 2020-09-18 上海璎黎药业有限公司 稠环衍生物、其制备方法、中间体、药物组合物及应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1137733B (de) * 1954-06-05 1962-10-11 Chem Fab Promonta G M B H Verfahren zur Herstellung von Aryl- und Thienylmethylphenylalkylaminen
US5300499A (en) * 1992-09-02 1994-04-05 Allergan, Inc. 5-substituted 3-thiophene sulfonamides as antiglaucoma agents
FR2742149B1 (fr) * 1995-12-11 1998-02-13 Inst Nat Sante Rech Med Nouveaux derives de 2-naphtamides et leurs applications therapeutiques
CA2207141A1 (en) * 1996-07-15 1998-01-15 David Thompson Berg Benzothiophene compounds, and uses and formulations thereof
DE19718334A1 (de) * 1997-04-30 1998-11-05 Boehringer Ingelheim Pharma Neue Benzylaminderivate und Phenylethylaminderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6531459B1 (en) 1997-12-17 2003-03-11 Schering Aktiengesellschaft Vitamin D derivatives with phosphorus atoms in the side chains
US6110963A (en) * 1998-05-12 2000-08-29 American Home Products Corporation Aryl-oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6218430B1 (en) 1998-08-24 2001-04-17 Ligand Pharmaceuticals Incorporated Vitamin D3 mimics
FR2801307B1 (fr) * 1999-11-24 2002-12-06 Galderma Res & Dev Analogues de la vitamine d
WO2003101978A1 (en) 2002-05-29 2003-12-11 Eli Lilly And Company Phenyl-thiophene type vitamin d receptor modulators
DE60326082D1 (de) 2002-11-22 2009-03-19 Lilly Co Eli Modulatoren von vitamin d rezeptoren
EP1587906A2 (de) 2003-01-10 2005-10-26 Eli Lilly And Company Vesikansbehandlung mit vitamin-d-rezeptormodulatoren des phenyl-phenyl-typs
WO2004063348A2 (en) 2003-01-10 2004-07-29 Eli Lilly And Company Vesicant treatment with phenyl-thiophene type vitamin d receptor modulators
WO2005037755A2 (en) * 2003-10-14 2005-04-28 X-Ceptor Therapeutics, Inc. Bridged ring structures as pharmaceutical agents
EP1692123B1 (de) 2003-11-20 2008-05-28 Eli Lilly And Company Phenylfuranverbindungen als modulatoren des vitamin-d-rezeptors
US7750184B2 (en) 2003-11-20 2010-07-06 Eli Lilly And Company Vitamin D receptor modulators
WO2005051940A2 (en) * 2003-11-20 2005-06-09 Eli Lilly And Company Vitamin d receptor modulators
EP1687289A1 (de) * 2003-11-20 2006-08-09 Eli Lilly And Company Modulatoren des vitamin-d-rezeptors
CA2544501A1 (en) 2003-11-20 2005-06-09 Eli Lilly And Company Vitamin d receptor modulators
MX2007007439A (es) 2004-12-21 2007-09-06 Lilly Co Eli Moduladores del receptor de la vitamina d.
KR100931777B1 (ko) 2004-12-21 2009-12-14 일라이 릴리 앤드 캄파니 비타민 d 수용체 조절제

Also Published As

Publication number Publication date
CA2544522A1 (en) 2005-06-09
EP1687292B1 (de) 2007-08-22
DE602004008505T2 (de) 2008-05-21
US20070149810A1 (en) 2007-06-28
US20100076065A1 (en) 2010-03-25
EP1687292A2 (de) 2006-08-09
DE602004008505D1 (de) 2007-10-04
WO2005051940A3 (en) 2005-08-11
JP2007512329A (ja) 2007-05-17
ES2291981T3 (es) 2008-03-01
US7582775B2 (en) 2009-09-01
WO2005051940A2 (en) 2005-06-09
US7897789B2 (en) 2011-03-01
JP4717006B2 (ja) 2011-07-06

Similar Documents

Publication Publication Date Title
CY1108988T1 (el) Διαμορφωτες υποδοχεα βιταμινης d
CY1109341T1 (el) Διαμορφωτες υποδοχεα βιταμινης d τυπου φαινυλο-θειοφαινιου
DE602004008505D1 (de) Modulatoren des vitamin-d-rezeptors
WO2005051893A3 (en) Vitamin d receptor modulators
ATE396982T1 (de) Phenylfuranverbindungen als modulatoren des vitamin-d-rezeptors
DE60324909D1 (de) (20s)-1alpha-hydroxy-2alpha-methyl und 2beta-methyl-19-nor vitamin d3 und ihre verwendung
DE69911596D1 (de) 24-hydroxy vitamin d, deren analogen und verwendungen
MY140767A (en) Compounds, methods and compositions
BR0313676A (pt) Derivados de pirimidina e uso destes como moduladores cb2
MX2010006379A (es) Moduladores de la secretasa gamma.
MX2010005028A (es) Moduladores de gamma secretasa.
ATE360000T1 (de) Oxim-analoga von 1-alpha,25-dihydroxy-vitamin-d3 mit geringer calcemischer wirkung
WO2005051898A3 (en) Vitamin d receptor modulators
AU2003233735A8 (en) 24-sulfoximine vitamin d3 compounds
MX2023013942A (es) Usos de un modulador de somatostatina para el tratamiento de enfermedades.
ATE165819T1 (de) 26,28-methylen-1alpha,25-dihydroxy-vitamin-d2- verbindungen
ATE455749T1 (de) Verbindungen mit verbrückten ringen als pharmazeutische mittel
WO2004054968A3 (en) 25-so2-substituted analogs of 1alpha, 25-dihydroxyvitamin d3 (calcitriol)
EP1576180A4 (de) Komponenten des ampk-wegs
WO2004063345A3 (en) Vesicant treatment with phenyl-phenyl type vitamin d receptor modulators
MXPA05004192A (es) Tetralinas e indanos sustituidos.
NO20052199L (no) Substituerte tetraliner og indaner
ATE417035T1 (de) Vitamin-d3-analoga zur prävention undbehandlung von knochenerkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties